Lisinopril and Pioglitazone: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Lisinopril
Pioglitazone
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You're taking lisinopril (a blood pressure medicine) along with pioglitazone (a diabetes medicine). When these two are used together, there's a chance your blood sugar could dip a bit lower than expected. This is a possible effect based on how ACE inhibitors like lisinopril may work alongside diabetes drugs, not something that happens to everyone.
The good news is this is very manageable. Watch for signs of low blood sugar like shakiness, sweating, dizziness, or feeling suddenly hungry or confused. Keep taking both medicines as prescribed, and your care team can check your sugar more often and fine-tune your doses if needed.
Effect: Possible increased risk of hypoglycemia when an ACE inhibitor (lisinopril) is coadministered with an antidiabetic agent (pioglitazone).
- Direction: Enhanced glucose-lowering / hypoglycemic potential.
- Mechanism: Unknown; proposed improvement in insulin sensitivity with ACE inhibition. Neither agent is metabolically activated in a way that flips this.
- Evidence: Theoretical. A self-controlled case series found no increased serious hypoglycemia with ACE inhibitors plus secretagogues (possible exception: glimepiride).
- Onset: Unspecified.
- Management: More frequent glucose monitoring during therapy and after ACE inhibitor withdrawal; adjust antidiabetic dosing as needed.
What happens
An increased risk of hypoglycemia
Interaction Deep Dive
When ACE inhibitors are given together with antidiabetic medications, the likelihood of hypoglycemia may rise231. Should combined therapy be necessary, glucose levels should be checked more often, not only while the patient is being treated but also once the ACE inhibitor has been discontinued4. Adjusting the insulin dose may likewise be required23. Findings from a self-controlled case series indicate that using ACE inhibitors alongside insulin secretagogues does not correlate with higher rates of serious hypoglycemia, although glimepiride may be an exception5.
Why it happens (mechanism)
Unknown
How to manage this interaction
This interaction is usually easy to handle. Keep taking both lisinopril and pioglitazone exactly as prescribed unless your prescriber tells you otherwise.
- Your care team may check your blood sugar more often, both while you take these together and if lisinopril is ever stopped.
- Your diabetes medicine dose may need to be adjusted and individualized by your care team.
- Learn the signs of low blood sugar (shakiness, sweating, dizziness, confusion) and know how to treat it quickly.
Bring up any low-sugar episodes with your pharmacist or doctor so they can tailor your plan.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Using a self-controlled case series approach, investigators reviewed Medicare claims data from 5 states spanning 1999 to 2011 to assess simultaneous use of ACE inhibitors together with insulin secretagogues (glimepiride, glipizide, glyburide, nateglinide, and repaglinide) or metformin (serving as a negative control). The endpoint assessed was hospital presentation for serious hypoglycemia. During the observation period, the counts of serious hypoglycemic events were 8159, 14,353, 11,129, 1595, 2901, and 32,639 for glimepiride, glipizide, glyburide, nateglinide, repaglinide, and metformin, respectively. The confounder-adjusted rate ratio (RR) was not significantly raised with glipizide, glyburide, repaglinide, or metformin, but it was slightly elevated with glimepiride (RR, 1.23; 95% CI, 1.11 to 1.37) and slightly reduced with nateglinide (RR, 0.73; 95% CI, 0.56 to 0.96). Apart from glimepiride, these findings indicate that concurrent use of an ACE inhibitor and insulin secretagogues was not linked to an increased risk of serious hypoglycemia 5.
Common questions
Can I take Lisinopril and Pioglitazone together?
Combining lisinopril and pioglitazone may slightly raise the chance of low blood sugar, so monitor your glucose and watch for symptoms; your care team can adjust doses as needed. Keep taking both as prescribed. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Lisinopril and Pioglitazone interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Lisinopril and Pioglitazone interaction managed?
This interaction is usually easy to handle. Keep taking both lisinopril and pioglitazone exactly as prescribed unless your prescriber tells you otherwise. Your care team may check your blood sugar more often, both while you take these together and if lisinopril is ever stopped. Your diabetes medicine dose may need to be adjusted and individualized by your care team. Learn the signs of low blood su… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Lisinopril or Pioglitazone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (5)
- Product Information: Zestril(R) oral tablets, lisinopril oral tablets. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2014. DailyMed
- Product Information: TOUJEO(R) subcutaneous injection, insulin glargine subcutaneous injection. sanofi-aventis (per manufacturer), Bridgewater, NJ, 2015. DailyMed
- Product Information: AFREZZA(R) oral inhalation powder, insulin human oral inhalation powder. MannKind Corporation(TM) (per manufacturer), Danbury, CT, 2014. DailyMed
- Product Information: AMARYL(R) oral tablets, glimepiride oral tablets. Sanofi-Aventis U.S. LLC (per FDA), Bridgewater, NJ, 2013. DailyMed
- Hee Nam Y, Brensinger CM, Bilker WB, et al: Angiotensin-converting enzyme inhibitors used concomitantly with insulin secretagogues and the risk of serious hypoglycemia. Clin Pharmacol Ther 2022; 111(1):218-226. PubMed
Keep reading about Lisinopril
Keep reading about Pioglitazone
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist